Monkey Anti-B. pertussis antigens (Pertussis toxin, FHA and LPS) IgG ELISA kit, 96 tests, Quantitative

Basic information

  • Name

    Monkey Anti-B. pertussis antigens (Pertussis toxin, FHA and LPS) IgG ELISA kit, 96 tests, Quantitative

  • Price

    798 EUR

  • Size

    1 Kit

  • Catalog number

    960-210-PHG

More detailed information

Stock availability

Available

Category

ELISA Kit

Antibody type

N/A

Antibody host

N/A

Antibody conjugate

N/A

Technical datasheet

Contact Gentaur to request the datasheet or ask our specialists for more information.

Notes

The Monkey Anti-B. pertussis antigens (Pertussis toxin, FHA and LPS) IgG ELISA kit, 96 tests, Quantitative is manufactured for Research Use Only or for diagnostics purposes.

Description

This antibody needs to be stored at + 4°C in a fridge short term in a concentrated dilution. Freeze thaw will destroy a percentage in every cycle and should be avoided.Rhesus Monkeys proteins are often measured by ELISA on serum or plasma since consensus epitopes with the human ELISA are used for producing the antibodies of these ELISA test kits. Often cDNA of monkeys is used as alternative to human cDNA as a model for drug development. Monkeys are generally considered to be intelligent, particularly Old World monkeys.

Properties

E05 478 566 350 170 or Enzyme-Linked Immunosorbent Assays,E05 478 566 350 170 or Enzyme-Linked Immunosorbent Assays

Test

ELISA Enzyme-linked immunosorbent assays Code 90320007 SNOMED

About

Immunoglobulin gamma, IgG, mouse monoclonal H&L chain clones or rabbit, goat polyclonal antibodies have 4 parts. There are 2 heavy chains, 2 light chains. The IgG antibody has 2 antigen binding sites. They represent 70% or more of serum antibodies. This antibody can be antigen purified or protein A or G purified. For storage sodium azide is added or you can call us to request azide free antibody preparations. These will need colder storage temperatures.

Additional isotype

IgG

Gene

Bacterial pathogen lipopolysaccharides (LPS) are the major outer surface membrane components present in almost all Gram-negative bacteria and act as extremely strong stimulators of innate or natural immunity in diverse eukaryotic species ranging from insects to humans. LPS consist of a poly- or oligosaccharide region that is anchored in the outer bacterial membrane by a specific carbohydrate lipid moiety termed lipid A. The lipid A component is the primary immunostimulatory center of LPS. With respect to immunoactivation in mammalian systems, the classical group of strongly agonistic (highly endotoxin) forms of LPS has been shown to be comprised of a rather similar set of lipid A types. In addition, several natural or derivative lipid A structures have been identified that display comparatively low or even no immunostimulation for a given mammalian species. Some members of the latter more heterogeneous group are capable of antagonizing the effects of strongly stimulatory LPS/lipid A forms. Agonistic forms of LPS or lipid A trigger numerous physiological immunostimulatory effects in mammalian organisms, but--in higher doses--can also lead to pathological reactions such as the induction of septic shock. Cells of the myeloid lineage have been shown to be the primary cellular sensors for LPS in the mammalian immune system. During the past decade, enormous progress has been obtained in the elucidation of the central LPS/lipid A recognition and signaling system in mammalian phagocytes. According to the current model, the specific cellular recognition of agonistic LPS/lipid A is initialized by the combined extracellular actions of LPS binding protein (LBP), the membrane-bound or soluble forms of CD14 and the newly identified Toll-like receptor 4 (TLR4)*MD-2 complex, leading to the rapid activation of an intracellular signaling network that is highly homologous to the signaling systems of IL-1 and IL-18. The elucidation of structure-activity correlations in LPS and lipid A has not only contributed to a molecular understanding of both immunostimulatory and toxic septic processes, but has also re-animated the development of new pharmacological and immuno-stimulatory strategies for the prevention and therapy of infectious and malignant diseases.